HighVista Strategies LLC Purchases New Position in Celldex Therapeutics, Inc. $CLDX

HighVista Strategies LLC purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 106,553 shares of the biopharmaceutical company’s stock, valued at approximately $2,168,000. HighVista Strategies LLC owned 0.16% of Celldex Therapeutics at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Lombard Odier Asset Management USA Corp acquired a new position in shares of Celldex Therapeutics during the 2nd quarter worth approximately $419,000. Bollard Group LLC acquired a new stake in Celldex Therapeutics in the 2nd quarter valued at $399,000. Jump Financial LLC increased its holdings in Celldex Therapeutics by 53.3% in the 2nd quarter. Jump Financial LLC now owns 29,503 shares of the biopharmaceutical company’s stock worth $600,000 after acquiring an additional 10,255 shares in the last quarter. Invesco Ltd. lifted its holdings in Celldex Therapeutics by 19.9% during the second quarter. Invesco Ltd. now owns 62,886 shares of the biopharmaceutical company’s stock valued at $1,280,000 after purchasing an additional 10,443 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in shares of Celldex Therapeutics during the second quarter worth about $238,000.

Wall Street Analyst Weigh In

CLDX has been the subject of several research reports. Wells Fargo & Company cut their price objective on Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating for the company in a research note on Wednesday, August 20th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $62.00 target price on shares of Celldex Therapeutics in a report on Wednesday, September 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. Citigroup lowered their price target on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating on the stock in a research report on Wednesday, August 20th. Finally, HC Wainwright cut their price objective on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday, August 20th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $43.80.

Celldex Therapeutics Trading Up 0.4%

Shares of CLDX opened at $28.19 on Thursday. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $30.50. The firm has a market capitalization of $1.87 billion, a P/E ratio of -8.34 and a beta of 1.13. The firm has a 50-day moving average price of $26.29 and a 200 day moving average price of $23.75.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%. Equities research analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Richard M. Wright sold 49,298 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $24.00, for a total value of $1,183,152.00. Following the completion of the transaction, the insider directly owned 20,833 shares in the company, valued at approximately $499,992. This represents a 70.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.40% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.